1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases" is currently closed and not accepting applications.
Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases is sponsored by NIH National Center for Advancing Translational Sciences (NCATS). This program funds research teams to adapt the shared molecular etiology approach from oncology to rare diseases, focusing on clinical trials of drugs targeting shared molecular causes across multiple rare diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: See official notice. Confirm the full requirements in the official notice before applying.
The published deadline was March 10, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases is funded by NIH National Center for Advancing Translational Sciences (NCATS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read article